C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling

Circ Res. 2013 May 10;112(10):1355-64. doi: 10.1161/CIRCRESAHA.113.301325. Epub 2013 Mar 25.

Abstract

Rationale: C2238 atrial natriuretic peptide (ANP) minor allele (substitution of thymidine with cytosine in position 2238) associates with increased risk of cardiovascular events.

Objective: We investigated the mechanisms underlying the vascular effects of C2238-αANP.

Methods and results: In vitro, human umbilical vein endothelial cell were exposed to either wild-type (T2238)- or mutant (C2238)-αANP. Cell survival and apoptosis were tested by Trypan blue, annexin V, and cleaved caspase-3 assays. C2238-αANP significantly reduced human umbilical vein endothelial cell survival and increased apoptosis. In addition, C2238-αANP reduced endothelial tube formation, as assessed by matrigel. C2238-αANP did not differentially modulate natriuretic peptide receptor (NPR)-A/B activity with respect to T2238-αANP, as evaluated by intracellular cGMP levels. In contrast, C2238-αANP, but not T2238-αANP, markedly reduced intracellular cAMP levels in an NPR-C-dependent manner. Accordingly, C2238-αANP showed higher affinity binding to NPR-C, than T2238-αANP. Either NPR-C inhibition by antisense oligonucleotide or NPR-C gene silencing by small interfering RNA rescued survival and tube formation of human umbilical vein endothelial cell exposed to C2238-αANP. Similar data were obtained in human aortic endothelial cell with NPR-C knockdown. NPR-C activation by C2238-αANP inhibited the protein kinase A/Akt1 pathway and increased reactive oxygen species. Adenovirus-mediated Akt1 reactivation rescued the detrimental effects of C2238-αANP. Overall, these data indicate that C2238-αANP affects endothelial cell integrity through NPR-C-dependent inhibition of the cAMP/protein kinase A/Akt1 pathway and increased reactive oxygen species production. Accordingly, C2238-αANP caused impairment of acetylcholine-dependent vasorelaxation ex vivo, which was rescued by NPR-C pharmacological inhibition. Finally, subjects carrying C2238 minor allele showed early endothelial dysfunction, which highlights the clinical relevance of our results.

Conclusions: C2238-αANP reduces endothelial cell survival and impairs endothelial function through NPR-C signaling. NPR-C targeting represents a potential strategy to reduce cardiovascular risk in C2238 minor-allele carriers.

Keywords: Akt; T2238C gene variant; atrial natriuretic peptide; endothelial dysfunction; natriuretic peptide receptor type C.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Aorta / drug effects
  • Aorta / pathology
  • Aorta / physiopathology
  • Apoptosis / drug effects
  • Apoptosis / physiology
  • Atrial Natriuretic Factor / genetics*
  • Atrial Natriuretic Factor / pharmacology
  • Atrial Natriuretic Factor / physiology*
  • Cell Survival / drug effects
  • Cell Survival / physiology
  • Cells, Cultured
  • Cyclic AMP / physiology
  • Cyclic AMP-Dependent Protein Kinases / physiology
  • Cyclic GMP / physiology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology*
  • Endothelium, Vascular / physiopathology*
  • Genetic Variation / genetics*
  • Humans
  • In Vitro Techniques
  • Natriuretic Peptide, C-Type / physiology*
  • Proto-Oncogene Proteins c-akt / physiology
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / physiology*
  • Umbilical Veins / drug effects
  • Umbilical Veins / pathology
  • Umbilical Veins / physiopathology

Substances

  • Reactive Oxygen Species
  • Natriuretic Peptide, C-Type
  • Atrial Natriuretic Factor
  • Cyclic AMP
  • Proto-Oncogene Proteins c-akt
  • Cyclic AMP-Dependent Protein Kinases
  • Cyclic GMP